PAKLITAKSEL I KARBOPLATIN V LEChENII RASPROSTRANENNOGO NEMELKOKLETOChNOGO RAKA LEGKOGO: PREDVARITEL'NYE REZUL'TATY OTKRYTOGO PROSPEKTIVNOGO KLINIChESKOGO ISSLEDOVANIYa
- Authors: Gorbunova VA1, Marenich AF1, Reutova EV1, Sheveleva LP1, Karaseva NA1, Bogdanova NV1, Uskov DA1, Khasanov RS.1, Mukhametshina GZ1, Tuzikov SA1, Khorinko AV1, Ivanov RA1, Par VI1
-
Affiliations:
- Issue: No 6 (2010)
- Pages: 62-69
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278363
- ID: 278363
Cite item
Full Text
Abstract
About the authors
V A Gorbunova
A F Marenich
E V Reutova
L P Sheveleva
N A Karaseva
N V Bogdanova
D A Uskov
R Sh Khasanov
G Z Mukhametshina
S A Tuzikov
A V Khorinko
R A Ivanov
V I Par
References
- Bunn PA Jr. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol 1997;24(12):153-62.
- Giorgio CG, Pappalardo A, Russo A, et al. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2006;51(3):357-62.
- Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. JCO 2001;19(13):3210-18.
- Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. JCO 2002;20(17):3578-85.
- Kosmidis P, Mylonakis N, Skarlos D, et al. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2000;11(7):799-805.
- Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 1995;13:1860-70.
- Ozols RF, Herbst RS, Colson YL, et al. Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening - A Report From the American Society of Clinical Oncology. JCO 2007;25:146-62.
- Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-49.
- Scagliotti GV, Marinis F, Rinaldi M, et al. Phasse III Randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. JCO 2002;20:4285-91.
- Schiller JH, Harrington D, Belani CP, et al. for the Eastern Cooperative Oncology Group Comparison of four chemotheraty regimens for advanced non-small-cell lung cancer. NEJM 2002;346(2):92-8.
- Stathopoulos GP, Veslemes M, Georgatou N, et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004;15(7):1048-55.
Supplementary files
![](/img/style/loading.gif)